The HERTHENA-Lung02 trial, a phase 3 trial of patritumab deruxtecan vs. platinum-based chemotherapy in EGFR-mutated NSCLC after EGFR TKI failure is enrolling at present (NCT05338970) (Table 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.